Skip to content

Areas of Focus

At Acadia, we see promise in therapeutic areas where the unmet need remains high.

What We Do

From Parkinson’s disease psychosis to Rett syndrome, we are fiercely committed to addressing unmet needs in neuroscience. Learn about the areas where we aim to elevate life for patients.

Parkinson’s Disease Psychosis (PDP)

PDP is typically characterized by hallucinations and delusions. Around 50% of patients with Parkinson’s disease may experience hallucinations and/or delusions over the course of their disease.

Rett Syndrome (RTT)

RTT is a rare neurodevelopmental disorder that occurs primarily in females following apparently normal development for the first 6-18 months of life. RTT occurs worldwide in approximately one of every 10,000 to 15,000 female births (6,000 to 9,000 patients in the U.S.).

Alzheimer’s Disease Psychosis (ADP)

Approximately 6 million people in the United States are living with Alzheimer’s disease, with this number projected to rise as the elderly population grows. Hallucinations and delusions associated with ADP affect around 30% of patients with AD dementia.

Get in Touch

How can we help? Click here to get in touch with us directly. Our team is committed to supporting you.

To report an Adverse Event or Product Complaint please call (844) 422-2342.

Important Note

You are now being redirected

You are now leaving acadia.com

You are about to leave acadia.com. You will be redirected to a third party website not affiliated with Acadia Pharmaceuticals Inc.
Do you want to continue?

You are leaving our {{LEAVING_REGION}} website and going to our {{ENTERING_REGION}} website, which is in {{ENTERING_LANGUAGE}}.
The information you are about to be referred to may not comply with the local regulatory requirements.
Do you want to continue?

You are now being directed to another Acadia website that contains information about specific treatment(s).
Do you want to continue?

Continue